Last Updated:
10 Mar 2026, 03:29:50 PM (IST)
ZIM Laboratories Limited
NSE: ZIMLAB BSE: ZIMLAB
NSE
67.22
-0.25 (-0.37%)
Prev Close
67.47
Open Price
68
Volume
89,124
Today Low / High
66.55 / 69.81
52 WK Low / High
65 / 127
Range
64 - 71
BSE
67.35
-0.22 (-0.33%)
Prev Close
67.57
Open Price
67.74
Volume
2,943
Today Low / High
66.56 / 69.48
52 WK Low / High
64.1 / 126.95
Range
64 - 71
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 67.22 (target range: 64 - 71), reflecting a change of -0.25 (-0.37054%). On the BSE, it is listed at 67.35 (target range: 64 - 71), showing a change of -0.22 (-0.32559%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
ZIM Laboratories Limited Graph
ZIM Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for ZIM Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 67.22, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 67.35 | 68.02 | 61.22 - 74.83 |
| 68.70 | 54.96 - 82.44 | ||
| 69.37 | 48.56 - 90.18 | ||
| Bearish Scenario | 67.35 | 66.68 | 60.01 - 73.34 |
| 66.00 | 52.80 - 79.20 | ||
| 65.33 | 45.73 - 84.93 |
Overview of ZIM Laboratories Limited
ISIN
INE518E01015
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
61,640
Market Cap
3,362,770,200
Last Dividend
0
Official Website
IPO Date
2022-11-25
DCF Diff
76.35
DCF
-7
Financial Ratios Every Investor Needs
Stock Dividend of ZIMLAB
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2019-09-19 | September 19, 19 | 0.16667 | 0.0556 | 2019-09-21 | 2019-10-30 | |
| 2018-09-03 | September 03, 18 | 0.16667 | 0.0556 | 2018-09-04 | 2018-09-05 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 374.12 Cr | 301.12 Cr | 73.00 Cr | 0.1951 | 21.72 Cr | 63.23 Cr | 20.05 Cr | 12.17 Cr | 2.50 | 49.51 Cr | 0.0325 |
| 2024-03-31 | 367.52 Cr | 181.54 Cr | 185.98 Cr | 0.5060 | 19.60 Cr | 11.25 Cr | 109.81 Cr | 17.25 Cr | 3.54 | 45.48 Cr | 0.0469 |
| 2023-03-31 | 398.53 Cr | 308.15 Cr | 90.38 Cr | 0.2268 | 18.74 Cr | 13.12 Cr | 31.08 Cr | 24.43 Cr | 5.01 | 58.20 Cr | 0.0613 |
| 2022-03-31 | 330.73 Cr | 161.24 Cr | 167.00 Cr | 0.5050 | 16.87 Cr | 11.89 Cr | 22.46 Cr | 14.55 Cr | 2.99 | 45.26 Cr | 0.0440 |
| 2021-03-31 | 307.35 Cr | 159.25 Cr | 148.09 Cr | 0.4818 | 13.87 Cr | 8.44 Cr | 24.72 Cr | 7.32 Cr | 1.50 | 35.53 Cr | 0.0238 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.95 Cr | 472.02 Cr | 219.79 Cr | 252.2375 Cr | 117.80 Cr | 115.85 Cr | 86.47 Cr | 202.40 Cr | 0.00 Cr | 0.00 Cr | 0.05 Cr | 166.3646 Cr |
| 2024-03-31 | 9.60 Cr | 446.82 Cr | 208.08 Cr | 238.7458 Cr | 111.63 Cr | 102.03 Cr | 81.26 Cr | 180.45 Cr | 2.38 Cr | 0.00 Cr | 0.01 Cr | 159.4252 Cr |
| 2023-03-31 | 6.47 Cr | 341.58 Cr | 141.23 Cr | 200.3460 Cr | 62.00 Cr | 55.53 Cr | 53.71 Cr | 121.56 Cr | 4.41 Cr | 0.00 Cr | 0.05 Cr | 110.7871 Cr |
| 2022-03-31 | 3.42 Cr | 341.63 Cr | 165.92 Cr | 175.7095 Cr | 53.31 Cr | 49.89 Cr | 75.28 Cr | 106.86 Cr | 0.00 Cr | 0.00 Cr | 0.05 Cr | 145.9099 Cr |
| 2021-03-31 | 1.39 Cr | 324.78 Cr | 164.03 Cr | 160.7500 Cr | 82.32 Cr | 80.93 Cr | 54.35 Cr | 105.24 Cr | 8.76 Cr | 0.00 Cr | 0.05 Cr | 142.0355 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 41.1546 Cr | -39.9270 Cr | -9.1045 Cr | 0.3569 Cr | -7.6536 Cr | 1.9466 Cr | -40.7977 Cr | 18.0094 Cr | 6.7773 Cr | -0.0569 Cr | 3.7335 Cr |
| 2024-03-31 | 16.2782 Cr | -73.0126 Cr | 59.5340 Cr | -57.6450 Cr | 3.1797 Cr | 9.6002 Cr | -73.9232 Cr | 17.2464 Cr | 47.3691 Cr | -0.0493 Cr | -27.5567 Cr |
| 2023-03-31 | 38.1682 Cr | -36.2035 Cr | 0.5456 Cr | 1.5003 Cr | 3.0002 Cr | 6.4205 Cr | -36.6679 Cr | 35.3550 Cr | 8.4738 Cr | -0.0585 Cr | 21.5780 Cr |
| 2022-03-31 | 49.2061 Cr | -14.5713 Cr | -32.9705 Cr | 33.9808 Cr | 2.0278 Cr | 3.4203 Cr | -15.2253 Cr | 21.0425 Cr | -30.2384 Cr | -0.1678 Cr | -20.9370 Cr |
| 2021-03-31 | 31.8513 Cr | -5.8809 Cr | -25.9742 Cr | 25.3742 Cr | -0.0685 Cr | 1.3925 Cr | -6.4771 Cr | 15.4120 Cr | -9.4890 Cr | -0.0244 Cr | 2.0419 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 108.66 Cr | 69.21 Cr | 39.45 Cr | 0.3631 | 7.77 Cr | 4.40 Cr | 0.90 | 12.81 Cr | 0.0405 |
| 2025-09-30 | 88.71 Cr | 60.94 Cr | 27.77 Cr | 0.3130 | 0.77 Cr | -0.42 Cr | -0.09 | 7.80 Cr | -0.0048 |
| 2025-06-30 | 71.76 Cr | 30.01 Cr | 41.75 Cr | 0.5818 | -0.60 Cr | -1.87 Cr | -0.38 | 5.74 Cr | -0.0261 |
| 2025-03-31 | 108.73 Cr | 48.26 Cr | 60.48 Cr | 0.5562 | 9.31 Cr | 4.88 Cr | 1.00 | 16.31 Cr | 0.0449 |
| 2024-12-31 | 96.33 Cr | 41.25 Cr | 55.08 Cr | 0.5717 | 6.68 Cr | 4.00 Cr | 0.82 | 13.32 Cr | 0.0415 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 3.91 Cr | 1.11 Cr | 5.01 Cr | 102.08 Cr | 95.59 Cr | 226.82 Cr | 197.28 Cr | 470.14 Cr | 218.81 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 2.04 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -252.24 Cr |
| 2025-03-31 | 1.95 Cr | 0.09 Cr | 2.04 Cr | 107.00 Cr | 86.47 Cr | 231.31 Cr | 202.40 Cr | 472.02 Cr | 219.79 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 5.81 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -242.76 Cr |
| 2024-09-30 | 5.08 Cr | 0.94 Cr | 6.02 Cr | 81.59 Cr | 67.93 Cr | 191.62 Cr | 197.75 Cr | 427.36 Cr | 184.59 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -1.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 4.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 4.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 2.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 0.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2022-12-22 | December 22, 22 | 3:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Executive Chairman & MD
Anwar Siraj Daud
Gender: Not Specified
Year Born:
Chief Executive Officer & Executive Director
Chandrashekhar Mainde
Gender: Not Specified
Year Born:
Director of Business Development & Executive Director
Niraj Pukhraj Dhadiwal
Gender: male
Year Born: 1967
Company Secretary & Compliance Officer
Piyush Siddheshwar Nikhade
Gender: male
Year Born:
Head of ODS Business, Formulations of Domestic, ROW & Emerging Markets & Director
Prakash Pralhadrao Sapkal
Gender: male
Year Born: 1968
Chief Financial Officer
Shyam Mohan Patro
Gender: male
Year Born:
Senior Vice President of Technical Services
Vijay Fudke
Gender: male
Year Born:
Director of Finance & Executive Director
Zulfiquar Murtaza Kamal
Gender: male
Year Born: 1961
FAQs about ZIM Laboratories Limited
Who is the CEO of the company?
The CEO is Anwar Siraj Daud.
What is the current market price of the stock?
The current price is ₹69.00.
What is the 52-week price range?
The range is ₹65.52-127.
What is the market capitalization of the company?
The market capitalization is ₹336.28 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 48.16.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of ZIM Laboratories Limited (ISIN: INE518E01015) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹336.28 crores and an average daily volume of 61,640 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.